All In Biotech

Drug Trial Radar · NCT05171062

Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer

Safety and Tolerability of Bexmarilimab Plus Pembrolizumab for Patients With Advanced (Inoperable or Metastatic) Non-small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jun 2023

Primary completion

Dec 2025

Study completion Dec 2026

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Faron Pharmaceuticals Ltd
First posted
Dec 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study enrolls patients with Non-small cell lung cancer and treats them with the investigational drug Bexmarilimab (FP-1305) plus standard of care Pembrolizumab to block Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1). Treating with an antiCLEVER-1 antibody, such as bexmarilimab, could lead to immune system activation, which, in turn, may lead to cancer elimination.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • bexmarilimab (FP-1305)Drug

    standard 3+3 dose escalation trial of bexmarilimab (FP-1305)

  • PembrolizumabDrug

    Pembrolizumab 200mg IV is administered in 4 planned bexmarilimab dose escalation cohorts

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: Cycle 2 plus 3 weeks (21 days following the first dose of both study drugs)
  2. Programmed Death Cell Ligand 1 (PD-L1) levelTime frame: Cycle 1 (21 days), pre-dose levels at start of Cycle 3 (42 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mays Cancer Center, UT Health San Antonio

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.